Out Licensing
Our pre-clinical stage assets include ALPHA-0602, ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s), which are expressed in several cell types in the central nervous system and in peripheral tissues, promotes cell survival, regulates certain inflammatory processes, and play a significant role in regulating lysosomal function and microglial responses to disease. Its intended use for the treatment of neurodegenerative diseases has been patented by the Company and ALPHA-0602 has been granted an Orphan Drug Designation for the treatment of ALS by the FDA. ALPHA-0702 and ALPHA-0802 are Granulin Epithelin Motifs, (“GEMs”), derived from full length progranulin which have therapeutic potential across multiple neurodegenerative diseases. GEMs have been shown to be important in regulating cell growth, survival, repair, and inflammation. ALPHA-0702 and ALPHA-0802 are designed to deliver this with potentially lower toxicity, and greater therapeutic effect. We plan to seek to out-license the assets to interested third parties.
Alpha Cognition will entertain partnering opportunities with pharmaceutical companies that have commercialization infrastructure or R&D expertise in specific territories around the world. Please contact info@alphacognition.com
In Licensing
Alpha Cognition is looking for innovative products that will strengthen our Long term care commercialization capability or that are developmental in CNS conditions in Pre-IND to Phase 2a phases of development.
Contact info@alphacognition.com